Compare QCOM & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QCOM | NVO |
|---|---|---|
| Founded | 1985 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.9B | 269.6B |
| IPO Year | 2009 | N/A |
| Metric | QCOM | NVO |
|---|---|---|
| Price | $138.29 | $39.83 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 11 |
| Target Price | ★ $170.89 | $51.00 |
| AVG Volume (30 Days) | 8.5M | ★ 19.9M |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | 2.62% | ★ 3.19% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $44,284,000,000.00 | N/A |
| Revenue This Year | $1.03 | N/A |
| Revenue Next Year | $0.76 | $4.39 |
| P/E Ratio | $48.86 | ★ $13.60 |
| Revenue Growth | ★ 13.66 | N/A |
| 52 Week Low | $120.80 | $35.85 |
| 52 Week High | $205.55 | $82.23 |
| Indicator | QCOM | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 38.28 | 35.79 |
| Support Level | $132.73 | N/A |
| Resistance Level | $163.23 | $50.30 |
| Average True Range (ATR) | 3.43 | 0.89 |
| MACD | 0.27 | 0.03 |
| Stochastic Oscillator | 32.86 | 28.36 |
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.